货号 (SKU)

包装规格

是否现货

价格

数量

Ab175571-100μg

100μg

现货

Ab175571-1mg

1mg

现货

Ab175571-5mg

5mg

现货

Ab175571-10mg

10mg

期货

基本信息

产品名称	Lampalizumab (anti-Complement Factor D), 补体因子 D 抗体
别名	兰帕利珠单抗 \| Lampalizumab(抗补体因子 D)
英文别名	Adipsin antibody \| Adipsin/complement factor D antibody \| Adn antibody \| C3 convertase activator antibody \| CFAD_HUMAN antibody \| CFD antibody \| Complement factor D antibody \| complement factor D preproprotein antibody \| D component of complement antibody
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CFD
种属反应性	人(Human),兔(Rabbit),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	补体因子 D 抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	25.7 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1278466-20-8
分子类型	抗体

关联靶点（人）

CFD Tchem 补体因子D(Complement factor D) (0 活性数据)

点击查看靶蛋白信息： CFD

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

SEC: Lampalizumab (anti-Complement Factor D) (Ab175571)

Lampalizumab (anti-Complement Factor D) (Ab175571) - SEC
The purity of Lampalizumab (anti-Complement Factor D) (Ab175571) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	货号
ZJ24F1013155	分析证书	Ab175571
ZJ24F1013154	分析证书	Ab175571
ZJ24F1013153	分析证书	Ab175571
ZJ24F0405069	分析证书	Ab175571
ZJ24F0405068	分析证书	Ab175571
ZJ24F0405067	分析证书	Ab175571

引用文献

1. Tanhehco EJ, Kilgore KS, Liff DA, Murphy KL, Fung MS, Sun WN, Sun C, Lucchesi BR. (1999) The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system.. Transplant Proc, 31 (5): (2168-71). [PMID:10456004]
2. Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, Vaughn WK, Fraser Jr CD. (2001) Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits.. J Thorac Cardiovasc Surg, 122 (1): (113-22). [PMID:11436043]
3. Charbel Issa P, Chong NV, Scholl HP. (2011) The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.. Graefes Arch Clin Exp Ophthalmol, 249 (2): (163-74). [PMID:21127893]
4. Do DV, Pieramici DJ, van Lookeren Campagne M, Beres T, Friesenhahn M, Zhang Y, Strauss EC, Phase Ia Investigators. (2014) A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy.. Retina (Philadelphia, PA), 34 (2): (313-20). [PMID:23842100]
5. Yang CY, Phillips JG, Stuckey JA, Bai L, Sun H, Delproposto J, Brown WC, Chinnaswamy K.. (2016) Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.. ACS Med Chem Lett, 7 (12): (1092-1096). [PMID:27994744] [10.1021/acsmedchemlett.6b00299]
6. Vulpetti A, Randl S, Rüdisser S, Ostermann N, Erbel P, Mac Sweeney A, Zoller T, Salem B, Gerhartz B, Cumin F, Hommel U, Dalvit C, Lorthiois E, Maibaum J.. (2017) Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.. J Med Chem, 60 (5): (1946-1958). [PMID:28157311] [10.1021/acs.jmedchem.6b01684]
7. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N. (2020) Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.. J Med Chem, 63 (17): (9856-9875). [PMID:32856916] [10.1021/acs.jmedchem.0c01020]
8. White, R T RT and 7 more authors.. (1992) Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue.. The Journal of biological chemistry, (5): [PMID:1374388]
9. Johnson, D M DM, Gagnon, J J and Reid, K B KB.. (1984) Amino acid sequence of human factor D of the complement system. Similarity in sequence between factor D and proteases of non-plasma origin.. FEBS letters, (30): [PMID:6363133]
10. Niemann, M A MA, Bhown, A S AS, Bennett, J C JC and Volanakis, J E JE.. (1984) Amino acid sequence of human D of the alternative complement pathway.. Biochemistry, (22): [PMID:6383466]
11. and Davis, A E AE.. (1980) Active site amino acid sequence of human factor D.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:6776531]
12. Johnson, D M DM, Gagnon, J J and Reid, K B KB.. (1980) Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site.. The Biochemical journal, (1): [PMID:6821372]
13. Volanakis, J E JE, Bhown, A A, Bennett, J C JC and Mole, J E JE.. (1980) Partial amino acid sequence of human factor D:homology with serine proteases.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:6987665]
14. Kim, S S, Narayana, S V SV and Volanakis, J E JE.. (1995) Crystal structure of a complement factor D mutant expressing enhanced catalytic activity.. The Journal of biological chemistry, (13): [PMID:7592653]
15. Narayana, S V SV and 8 more authors.. (1994) Structure of human factor D. A complement system protein at 2.0 A resolution.. Journal of molecular biology, (14): [PMID:8289289]
16. Sprong, Tom T and 6 more authors.. (2006) Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.. Blood, (15): [PMID:16527897]
17. Maibaum, Jürgen J and 28 more authors.. (2016) Small-molecule factor D inhibitors targeting the alternative complement pathway.. Nature chemical biology, [PMID:27775713]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Lampalizumab (anti-Complement Factor D), 补体因子 D 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Lampalizumab (anti-Complement Factor D), 补体因子 D 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器